ClinicalTrials.gg
CompletedNCT02197416Updated Jun 4, 2020Results posted

Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

A Phase 3 interventional study of dabigatran etexilate in Venous Thromboembolism and Secondary Prevention, sponsored by Boehringer Ingelheim. Completed at 62 sites in 22 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2020-06-04.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
214
Allocation
Not applicable
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing dabigatran in Venous Thromboembolism — 1 open to participants now, 1 under way, none of them phase 3. Dabigatran · Venous Thromboembolism.

Enrollment
8th of 17
214 · median 148
Started
2014
with 1 other
Phase 3
6 of 17
none open now
Registered
13th of 17
by date
Lead sponsor
12 of 17
Boehringer Ingelheim

Among the 17 studies testing dabigatran in Venous Thromboembolism, this one is the 8th largest by enrollment, is one of 2 that started in 2014, is one of 6 in phase 3, and was the 13th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

1 of the 17 studies testing dabigatran in Venous Thromboembolism is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dabigatran

Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing dabigatran in Venous Thromboembolism, or all of them as a file.
02

Study summary

This open-label, single arm prospective cohort study will assess the safety of dabigatran etexilate in secondary prevention of venous thromboembolism in paediatric patients. Children from 0 to less than 18 years of age will be eligible to participate.

03

Conditions studied

  • Venous Thromboembolism
  • Secondary Prevention
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects 0 to less than 18 years of age at the time of / assent
  • Previously documented objective diagnosis of VTE, followed by completed course of initial VTE treatment for at least 3 months (in case of VKA - intended between 2 and 3) or completed study treatment (i.e. reached Visit 8) in the 1160.106 trial. Patients, who during the treatment phase of 1160.106 trial were switched from dabigatran etexilate to SOC arm for any reason, are not eligible for this study.
  • Presence of an unresolved clinical risk factor requiring further anticoagulation for secondary VTE prevention (e.g. central venous line, underlying disease, thrombophilia, etc.)
  • Written informed consent form (ICF) provided by the patient's parent or legal guardian and assent provided by the patient (if applicable) at the time of ICF signature according to local regulations.
  • Further inclusion criteria apply

Exclusion criteria

Exclusion criteria:

  • Conditions associated with an increased risk of bleeding
  • Renal dysfunction ( \< 50 mL/min/1.73m\^2 using the Schwartz formula) or requirement for dialysis. eGFR retesting during the screening period is allowed (once).
  • Active infective endocarditis
  • Subjects with a heart valve prosthesis requiring anticoagulation.
  • Hepatic disease: Active liver disease, including known active hepatitis A, B or C or Persistent (ALT) or aspartate transaminase (AST) or alkaline phosphatase (AP) > 3 × (ULN) within 3 months of screening
  • Pregnant or breast feeding females. Females who have reached menarche and are not using an acceptable method of , or do not plan to continue using this method throughout the study and / or do not agree to adhere to pregnancy testing required by this protocol
  • Patients in age group 0 to \< 2 years with gestational age at birth \< 37 weeks or with body weight lower than the 3rd percentile
  • Anemia ( \< 80g/L) or thrombocytopenia ( count \< 80 x 109/L) at screening. Transfusions during the screening period are allowed, provided that a satisfactory hemoglobin or platelet level is attained prior to visit 2
  • Patients who have taken restricted medication prior to first dose of study medication
  • Patients who have received an drug in the past 30 days prior to screening, except patients who have completed the treatment period (up to Visit 8) in 1160.106 trial
  • Patients who are allergic/sensitive to any component of the study medication including solvent
  • Patients or parents/legal guardians considered unreliable to participate in the trial per investigator judgment or any condition which would present a safety hazard to the patient based on investigator judgment
  • Further exclusion criteria apply
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
214 participants (actual)

Study arms

  • Experimental
    dabigatran etexilate

    Drug: dabigatran etexilate

Interventions

  • Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation

06

What researchers measure

Primary outcomes

  1. Event-free Probability of Recurrence of Venous Thromboembolism (VTE) at 6 and 12 Months

    The event-free probability of first recurrence of VTE were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months. Patients who did not experience recurrent VTE at the time of analysis, dropped out from the trial early, were lost to follow-up, or had died from non-VTE related cause were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.

    Time frame: At month 6 (Week 26) and 12 (Week 52) of on treatment period

  2. Event-free Probability of Major or Minor (Including Clinically Relevant Non-major (CRNM)) Bleeding Events at 6 and 12 Months

    The event-free probability of major or minor (including CRNM) bleeding event were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months. Patients who did not experience major or minor (including CRNM) bleeding event at the time of analysis, dropped out from the trial early, were lost to follow-up, or had died from non-bleeding related cause were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.

    Time frame: At month 6 (Week 26) and month 12 (Week 52) of on treatment period

  3. Event-free Probability of Mortality Overall and Related to Thrombotic or Thromboembolic Events at 6 and 12 Months

    The event-free probability of mortality overall and related to thrombotic or thromboembolic events were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months. Patients who did not experience mortality overall and related to thrombotic or thromboembolic events at the time of analysis, dropped out from the trial early, were lost to follow-up, were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.

    Time frame: At month 6 (Week 26) and 12 (Week 52) of on treatment period

Secondary outcomes

  1. Event-free Probability of Occurrence of Post-thrombotic Syndrome (PTS) at 6 and 12 Months

    The event-free probability of PTS were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months. Patients who did not experience PTS at the time of analysis, dropped out from the trial early, were lost to follow-up, or had died from non-PTS related cause were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.

    Time frame: At month 6 (Week 26) and 12 (Week 52) of on treatment period

  2. Percentage of Participants With Dabigatran Etexilate (DE) Dose Adjustments During on Treatment Period

    Percentage of participants with dabigatran etexilate dose adjustments during on treatment period. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.

    Time frame: From first DE administration to 3 days of residual effect period after last DE administration, up to 52 weeks+ 3 days

  3. Central Measurement of Activated Partial Thromboplastin Time (aPTT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)

    Time frame: At Visit 3 (day 4 after first dose of trial medication)

  4. Central Measurement of Activated Partial Thromboplastin Time (aPTT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)

    Time frame: Pharmacodynamics (PD) samples were collected from first dose of trial medication at day 1 and day 4, 22, 43, 85, 127, 183, 239 and 295 until last dose at day 365 and at post-titration (at least 3 days after dose adjustment) if needed, up to 365 days.

  5. Central Measurement of Ecarin Clotting Time (ECT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)

    Time frame: At Visit 3 (day 4 after first dose of trial medication)

  6. Central Measurement of Ecarin Clotting Time (ECT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)

    Time frame: Pharmacodynamics (PD) samples were collected from first dose of trial medication at day 1 and day 4, 22, 43, 85, 127, 183, 239 and 295 until last dose at day 365 and at post-titration (at least 3 days after dose adjustment) if needed, up to 365 days.

  7. Central Measurement of Diluted Thrombin Time (dTT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)

    Time frame: At Visit 3 (day 4 after first dose of trial medication)

  8. Central Measurement of Diluted Thrombin Time (dTT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)

    Time frame: dTT values were collected at day 4, 22, 43, 85, 127, 183, 239, and 295 until last dose at day 365 and at post-titration (at least 3 days after dose adjustment) if needed, up to 365 days.

07

Results

Posted Jun 4, 2020

Participant flow

This open label, single arm prospective cohort study was designed to assess the safety of dabigatran etexilate (DE) for secondary prevention of paediatric venous thromboembolism (VTE) with 12-month (365 days) treatment period followed by 28 days end of treatment follow-up. Results of participants were reported via 3 mutually exclusive age groups.

Participant flow — Overall Study
MilestoneDabigatran Etexilate (0 to < 2 Years)Dabigatran Etexilate (2 to <12 Years)Dabigatran Etexilate (12 to <18 Years)
Started943161
Completed839153
Not completed148
Withdrew: Other reasons025
Withdrew: Withdrawal by subject021
Withdrew: Protocol violation101
Withdrew: Adverse event001

Outcome measures

PrimaryEvent-free Probability of Recurrence of Venous Thromboembolism (VTE) at 6 and 12 Months

The event-free probability of first recurrence of VTE were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months. Patients who did not experience recurrent VTE at the time of analysis, dropped out from the trial early, were lost to follow-up, or had died from non-VTE related cause were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.

Time frame:
At month 6 (Week 26) and 12 (Week 52) of on treatment period
Reported as:
Number · Probability
Event-free Probability of Recurrence of Venous Thromboembolism (VTE) at 6 and 12 Months
ProbabilityDabigatran Etexilate (0 to < 2 Years)Dabigatran Etexilate (2 to <12 Years)Dabigatran Etexilate (12 to <18 Years)
6 months1.000 (1.000 to 1.000)1.000 (1.000 to 1.000)0.979 (0.937 to 0.993)
12 months1.000 (1.000 to 1.000)1.000 (1.000 to 1.000)0.979 (0.937 to 0.993)
PrimaryEvent-free Probability of Major or Minor (Including Clinically Relevant Non-major (CRNM)) Bleeding Events at 6 and 12 Months

The event-free probability of major or minor (including CRNM) bleeding event were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months. Patients who did not experience major or minor (including CRNM) bleeding event at the time of analysis, dropped out from the trial early, were lost to follow-up, or had died from non-bleeding related cause were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.

Time frame:
At month 6 (Week 26) and month 12 (Week 52) of on treatment period
Reported as:
Number · Probability
Event-free Probability of Major or Minor (Including Clinically Relevant Non-major (CRNM)) Bleeding Events at 6 and 12 Months
ProbabilityDabigatran Etexilate (0 to < 2 Years)Dabigatran Etexilate (2 to <12 Years)Dabigatran Etexilate (12 to <18 Years)
6 months0.889 (0.433 to 0.984)0.894 (0.706 to 0.965)0.753 (0.675 to 0.815)
12 months0.889 (0.433 to 0.984)0.831 (0.592 to 0.936)0.691 (0.603 to 0.763)
PrimaryEvent-free Probability of Mortality Overall and Related to Thrombotic or Thromboembolic Events at 6 and 12 Months

The event-free probability of mortality overall and related to thrombotic or thromboembolic events were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months. Patients who did not experience mortality overall and related to thrombotic or thromboembolic events at the time of analysis, dropped out from the trial early, were lost to follow-up, were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.

Time frame:
At month 6 (Week 26) and 12 (Week 52) of on treatment period
Reported as:
Number · Probability
Event-free Probability of Mortality Overall and Related to Thrombotic or Thromboembolic Events at 6 and 12 Months
ProbabilityDabigatran Etexilate (0 to < 2 Years)Dabigatran Etexilate (2 to <12 Years)Dabigatran Etexilate (12 to <18 Years)
6 months1.000 (1.000 to 1.000)1.000 (1.000 to 1.000)1.000 (1.000 to 1.000)
12 months1.000 (1.000 to 1.000)1.000 (1.000 to 1.000)1.000 (1.000 to 1.000)
SecondaryEvent-free Probability of Occurrence of Post-thrombotic Syndrome (PTS) at 6 and 12 Months

The event-free probability of PTS were provided by Kaplan-Meier estimation with its 95% confidence intervals (CIs) at 6 and 12 months. Patients who did not experience PTS at the time of analysis, dropped out from the trial early, were lost to follow-up, or had died from non-PTS related cause were considered as non-events and censored. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.

Time frame:
At month 6 (Week 26) and 12 (Week 52) of on treatment period
Reported as:
Number · Probability
Event-free Probability of Occurrence of Post-thrombotic Syndrome (PTS) at 6 and 12 Months
ProbabilityDabigatran Etexilate (0 to < 2 Years)Dabigatran Etexilate (2 to <12 Years)Dabigatran Etexilate (12 to <18 Years)
6 months1.000 (1.000 to 1.000)1.000 (1.000 to 1.000)0.979 (0.935 to 0.993)
12 months1.000 (1.000 to 1.000)1.000 (1.000 to 1.000)0.979 (0.935 to 0.993)
SecondaryPercentage of Participants With Dabigatran Etexilate (DE) Dose Adjustments During on Treatment Period

Percentage of participants with dabigatran etexilate dose adjustments during on treatment period. On treatment period was from first DE administration to 3 days of residual effect period after last DE administration.

Time frame:
From first DE administration to 3 days of residual effect period after last DE administration, up to 52 weeks+ 3 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Dabigatran Etexilate (DE) Dose Adjustments During on Treatment Period
Percentage of participantsDabigatran Etexilate (0 to < 2 Years)Dabigatran Etexilate (2 to <12 Years)Dabigatran Etexilate (12 to <18 Years)
Percentage of Participants With Dabigatran Etexilate (DE) Dose Adjustments During on Treatment Period66.739.521.1
SecondaryCentral Measurement of Activated Partial Thromboplastin Time (aPTT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)
Time frame:
At Visit 3 (day 4 after first dose of trial medication)
Reported as:
Mean · Second (s)
Central Measurement of Activated Partial Thromboplastin Time (aPTT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)
Second (s)Dabigatran Etexilate (0 to < 2 Years)Dabigatran Etexilate (2 to <12 Years)Dabigatran Etexilate (12 to <18 Years)
Central Measurement of Activated Partial Thromboplastin Time (aPTT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)46.6 ± 18.157.1 ± 70.456.8 ± 64.6
SecondaryCentral Measurement of Activated Partial Thromboplastin Time (aPTT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)
Time frame:
Pharmacodynamics (PD) samples were collected from first dose of trial medication at day 1 and day 4, 22, 43, 85, 127, 183, 239 and 295 until last dose at day 365 and at post-titration (at least 3 days after dose adjustment) if needed, up to 365 days.
Reported as:
Mean · Second (s)
Central Measurement of Activated Partial Thromboplastin Time (aPTT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)
Second (s)Dabigatran Etexilate (0 to < 2 Years)Dabigatran Etexilate (2 to <12 Years)Dabigatran Etexilate (12 to <18 Years)
Central Measurement of Activated Partial Thromboplastin Time (aPTT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)49.1 ± 26.857.3 ± 23.959.0 ± 80.8
SecondaryCentral Measurement of Ecarin Clotting Time (ECT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)
Time frame:
At Visit 3 (day 4 after first dose of trial medication)
Reported as:
Mean · Second (s)
Central Measurement of Ecarin Clotting Time (ECT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)
Second (s)Dabigatran Etexilate (0 to < 2 Years)Dabigatran Etexilate (2 to <12 Years)Dabigatran Etexilate (12 to <18 Years)
Central Measurement of Ecarin Clotting Time (ECT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)52.7 ± 17.664.3 ± 55.769.5 ± 30.3
SecondaryCentral Measurement of Ecarin Clotting Time (ECT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)
Time frame:
Pharmacodynamics (PD) samples were collected from first dose of trial medication at day 1 and day 4, 22, 43, 85, 127, 183, 239 and 295 until last dose at day 365 and at post-titration (at least 3 days after dose adjustment) if needed, up to 365 days.
Reported as:
Mean · Second (s)
Central Measurement of Ecarin Clotting Time (ECT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)
Second (s)Dabigatran Etexilate (0 to < 2 Years)Dabigatran Etexilate (2 to <12 Years)Dabigatran Etexilate (12 to <18 Years)
Central Measurement of Ecarin Clotting Time (ECT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)53.3 ± 19.466.6 ± 23.669.2 ± 28.7
SecondaryCentral Measurement of Diluted Thrombin Time (dTT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)
Time frame:
At Visit 3 (day 4 after first dose of trial medication)
Reported as:
Mean · Second (s)
Central Measurement of Diluted Thrombin Time (dTT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)
Second (s)Dabigatran Etexilate (0 to < 2 Years)Dabigatran Etexilate (2 to <12 Years)Dabigatran Etexilate (12 to <18 Years)
Central Measurement of Diluted Thrombin Time (dTT) at Visit 3 (After at Least Six Consecutive Dabigatran Etexilate (DE) Doses)37.9 ± 19.540.5 ± 14.645.3 ± 17.4
SecondaryCentral Measurement of Diluted Thrombin Time (dTT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)
Time frame:
dTT values were collected at day 4, 22, 43, 85, 127, 183, 239, and 295 until last dose at day 365 and at post-titration (at least 3 days after dose adjustment) if needed, up to 365 days.
Reported as:
Mean · Second (s)
Central Measurement of Diluted Thrombin Time (dTT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)
Second (s)Dabigatran Etexilate (0 to < 2 Years)Dabigatran Etexilate (2 to <12 Years)Dabigatran Etexilate (12 to <18 Years)
Central Measurement of Diluted Thrombin Time (dTT) at Post-titration (After at Least 3 Days Following Any Dabigatran Etexilate (DE) Dose Adjustment)40.0 ± 24.346.0 ± 18.643.4 ± 17.7

Adverse events

Collected over From first dose until last dose of study drug + 3 days of residual effect period, up to 52 weeks + 3 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dabigatran Etexilate (Treated Set)0/213 (0%)30/213 (14.1%)113/213 (53.1%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventDabigatran Etexilate (Treated Set)
PneumoniaInfections and infestations2/213
TonsillitisInfections and infestations2/213
Deep vein thrombosisVascular disorders2/213
Atrial flutterCardiac disorders1/213
Cardiac failureCardiac disorders1/213
MyocarditisCardiac disorders1/213
Pericardial effusionCardiac disorders1/213
Ventricular pre-excitationCardiac disorders1/213
Congenital anomalyCongenital, familial and genetic disorders1/213
Abdominal pain upperGastrointestinal disorders1/213
Most frequent other events
Showing 10 of 14
Most frequent other events
EventDabigatran Etexilate (Treated Set)
NasopharyngitisInfections and infestations34/213
HeadacheNervous system disorders34/213
NauseaGastrointestinal disorders17/213
DiarrhoeaGastrointestinal disorders15/213
DyspepsiaGastrointestinal disorders15/213
VomitingGastrointestinal disorders15/213
PyrexiaGeneral disorders15/213
Upper respiratory tract infectionInfections and infestations14/213
CoughRespiratory, thoracic and mediastinal disorders14/213
EpistaxisRespiratory, thoracic and mediastinal disorders14/213

Baseline characteristics

The treated set (TS) included all patients who were dispensed trial medication and had taken at least 1 dose of investigational treatment, which was used to assess safety endpoints, demographics and baseline characteristics.

Age, Continuous
Age, Continuous(Years)Dabigatran Etexilate (0 to < 2 Years)Dabigatran Etexilate (2 to <12 Years)Dabigatran Etexilate (12 to <18 Years)Total
Mean0.6 ± 0.56.8 ± 3.115.1 ± 1.612.8 ± 4.6
Sex: Female, Male
Sex: Female, Male(Participants)Dabigatran Etexilate (0 to < 2 Years)Dabigatran Etexilate (2 to <12 Years)Dabigatran Etexilate (12 to <18 Years)Total
Female4227096
Male52191117
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dabigatran Etexilate (0 to < 2 Years)Dabigatran Etexilate (2 to <12 Years)Dabigatran Etexilate (12 to <18 Years)Total
Hispanic or Latino0279
Not Hispanic or Latino941153203
Unknown or Not Reported0011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dabigatran Etexilate (0 to < 2 Years)Dabigatran Etexilate (2 to <12 Years)Dabigatran Etexilate (12 to <18 Years)Total
American Indian or Alaska Native0000
Asian0167
Native Hawaiian or Other Pacific Islander0000
Black or African American0448
White837149194
More than one race1113
Unknown or Not Reported0011
08

Study locations

62 sites
  • University of California Davis
    Sacramento, California 95817, United States
  • University of Miami
    Miami, Florida 33136, United States
  • St. Joseph's Children's Hospital
    Tampa, Florida 33607, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242-1083, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Alliance for Childhood Diseases
    Las Vegas, Nevada 89135, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Providence Sacred Heart Medical Center and Children's Hospital
    Spokane, Washington 99204, United States
  • AKH - Medical University of Vienna
    Wien, 1090, Austria
  • Brussels - UNIV UZ Brussel
    Brussel, 1090, Belgium
  • UNIV UZ Gent
    Gent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas
    Campinas, 13059-740, Brazil
  • Faculdade de Ciencias Medicas da UNICAMP
    Campinas, 13083970, Brazil
  • Instituto de Oncologia Pediatrica - IOP / GRAAC - UNIFESP
    Sao Paulo, 04039-001, Brazil
  • Kingston General Hospital
    Kingston, Ontario K7L 2V7, Canada
  • CHU Sainte-Justine
    Montreal, Ontario H3T 1C5, Canada
  • Children's Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • University Hospital Brno
    Brno, 61300, Czechia
  • University Hospital Olomouc
    Olomouc, 77900, Czechia
  • University Hospital Ostrava
    Ostrava, 70852, Czechia
  • University Hospital Plzen, Plzen-Lochotin
    Plzen - Lochotin, 304 60, Czechia
  • University Hospital Motol
    Prague, 15006, Czechia
  • Rigshospitalet, København, Børneonkologisk Afsnit 5002
    Copenhagen, 2100, Denmark
  • HOP Timone
    Marseille, 13005, France
  • Universitätsklinikum Essen AöR
    Essen, 45147, Germany
  • Universitätsmedizin Göttingen, Georg-August-Universität
    Göttingen, 37075, Germany
  • Universitätsklinikum Münster
    Münster, 48149, Germany
  • University Debrecen Hospital
    Debrecen, 4032, Hungary
  • Shaare Zedek Medical Center, Jerusalem 91031
    Jerusalem, 9103102, Israel
  • A.O. Univ. Policlinico "Paolo Giaccone"
    Palermo, 90127, Italy
  • Università degli Studi "La Sapienza"
    Roma, 00161, Italy
  • Osp. Pediatrico Bambin Gesù
    Roma, 00165, Italy
  • Ospedale Infantile Regina Margherita
    Torino, 10126, Italy
  • Children Intensive Care Hosp,Anaesthesiology Dept,Vilnius
    Vilnius, 08406, Lithuania
  • Instituto Nacional de Pediatría
    Mexico DF, 04530, Mexico
  • Haukeland Universitetssykehus
    Bergen, N-5021, Norway
  • Oslo Universitetssykehus HF, Rikshospitalet
    Oslo, N-0372, Norway
  • Children Rep.Clin.Hosp of MoH,Cardio Vas.surgery Dept, Kazan
    Kazan, 420138, Russian Federation
  • Science Res.Instit.CV Diseases,Scientific Res.Dept,Kemerovo
    Kemerovo, 650002, Russian Federation
  • Morozovskaya Children Clin.Hosp.,Haematological Dept, Moscow
    Moscow, 119049, Russian Federation
  • Child.CityClin.Hos.na.ZA Bashlyaeva MoscowHealth Dep,Cardiol
    Moscow, 125373, Russian Federation
  • St.Petersburg State Pediatric Univ.Ministry of Healthcare RF
    St. Petersburg, 194100, Russian Federation
  • Reg Clin.Hosp.#1,Healthcare Tyumen Region,Cardiovas.Surgery
    Tyument, 625023, Russian Federation
  • State Budget Healthcare Institution "Republican children's clinical hospital"
    Ufa, 450106, Russian Federation
  • Childr.CityClin.Hos#9,pediatric&Neonatal Neurol.Ekaterinburg
    Yekaterinburg, 620134, Russian Federation
  • Karolinska Univ. sjukhuset
    Solna, 171 65, Sweden
  • Universitäts-Kinderspital
    Zürich, 8032, Switzerland
  • Taichung Veterans General Hospital
    Taichung, 407, Taiwan
  • King Chulalongkorn Memorial Hospital
    Bangkok, 10330, Thailand
  • Cukurova Universitesi Tip Fakultesi Cocuk Sagligi
    Adana, 1330, Turkey
  • Hacettepe Universitesi Tip Fakultesi
    Ankara, 06100, Turkey
  • Akdeniz Universitesi Tip Fakultesi
    Antalya, 7058, Turkey
  • Istanbul Universitesi Cerrahpasa Tip Fakultesi
    Istanbul, 34098, Turkey
  • Istanbul Saglik Bilimleri Uni. Kanuni Sultan Suleyman EAH
    Istanbul, 34303, Turkey
  • Ege Universitesi Tip Fakultesi Cocuk Hematolojisi Bilim Dali
    Izmir, 35040, Turkey
  • Necmettin Erbakan Universitesi Meram Tip Fakultesi
    Konya, 42080, Turkey
  • Reg.Children Hosp.Dnipropetrovsk
    Dnipropetrovsk, 49100, Ukraine
  • Western Ukrainian Spec.Children Med.Center,Lviv
    Lviv, 79035, Ukraine
  • Reg.Children Hosp,Vinnytsia
    Vinnytsya, 21029, Ukraine
09

References and documents

Publications

  • Brandao LR, Tartakovsky I, Albisetti M, Halton J, Bomgaars L, Chalmers E, Luciani M, Saracco P, Felgenhauer J, Lvova O, Simetzberger M, Sun Z, Mitchell LG. Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia. Blood Adv. 2022 Nov 22;6(22):5908-5923. doi: 10.1182/bloodadvances.2021005681. PubMed 36150047 ↗
  • Brandao LR, Albisetti M, Halton J, Bomgaars L, Chalmers E, Mitchell LG, Nurmeev I, Svirin P, Kuhn T, Zapletal O, Tartakovsky I, Simetzberger M, Huang F, Sun Z, Kreuzer J, Gropper S, Brueckmann M, Luciani M; DIVERSITY Study Investigators. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2020 Feb 13;135(7):491-504. doi: 10.1182/blood.2019000998. Erratum In: Blood. 2020 May 7;135(19):1720. doi: 10.1182/blood.2020005941. PubMed 31805182 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Oct 2019, 60 months.

Results were first posted in Jun 2020, 7 months after primary completion.

Of 47 phase 3 interventional studies under Venous Thromboembolism, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2014
First posted
Jul 22, 2014
StartActual
Sep 29, 2014
Primary completionActual
Oct 16, 2019
CompletionActual
Nov 19, 2019
Results first posted
Jun 4, 2020
Last update
Jun 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02197416
Responsible party
Sponsor
First posted
Jul 22, 2014
Start date
Sep 29, 2014
Primary completion
Oct 16, 2019
Completion
Nov 19, 2019
Results posted
Jun 4, 2020
Last update
Jun 4, 2020

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion